MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Milei Threatens Falkland Oil Firms With Sanctions 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Add as a preferred source on Google
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2018 -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its senior management team are scheduled to present at four upcoming Investor Conferences.
2018 RBC Capital Markets Global Healthcare Conference
Date: Thursday, February 22, 2018
Presentation: 8:00-8:25 AM ET
Webcast available under Investor Relations tab at CRISPRTx.com
Barclays Global Healthcare Conference
Date: Tuesday, March 13, 2018
Presentation: 3:20-3:45 PM ET
Guggenheim Conference on Disruptive Technologies in Immuno-Oncology
Date: March 27th, 2018
17th Annual Needham Healthcare Conference
Date: March 28th, 2018
Presentation: 3:30 PM ET
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.
MEDIA CONTACT:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290 [email protected]
INVESTOR CONTACT:
Chris Erdman
+1 617.307.7227 [email protected]
Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843 [email protected]
